Ghent University Academic Bibliography

Advanced

Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer

N NEYMARK, P LIANES, EF SMIT and Jan Van Meerbeeck UGent (2005) PHARMACOECONOMICS. 23(11). p.1155-1166
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
journal title
PHARMACOECONOMICS
Pharmacoeconomics
volume
23
issue
11
pages
1155-1166 pages
publisher
ADIS INTERNATIONAL LTD
Web of Science type
Article
Web of Science id
000233761100007
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
2.198 (2005)
JCR rank
77/191 (2005)
JCR quartile
2 (2005)
ISSN
1170-7690
language
English
UGent publication?
yes
classification
A1
id
332383
handle
http://hdl.handle.net/1854/LU-332383
date created
2006-04-24 15:54:00
date last changed
2016-12-19 15:44:10
@article{332383,
  author       = {NEYMARK, N and LIANES, P and SMIT, EF and Van Meerbeeck, Jan},
  issn         = {1170-7690},
  journal      = {PHARMACOECONOMICS},
  language     = {eng},
  number       = {11},
  pages        = {1155--1166},
  publisher    = {ADIS INTERNATIONAL LTD},
  title        = {Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer},
  volume       = {23},
  year         = {2005},
}

Chicago
NEYMARK, N, P LIANES, EF SMIT, and Jan Van Meerbeeck. 2005. “Economic Evaluation of Three Two-drug Chemotherapy Regimens in Advanced Non-small-cell Lung Cancer.” Pharmacoeconomics 23 (11): 1155–1166.
APA
NEYMARK, N., LIANES, P., SMIT, E., & Van Meerbeeck, J. (2005). Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. PHARMACOECONOMICS, 23(11), 1155–1166.
Vancouver
1.
NEYMARK N, LIANES P, SMIT E, Van Meerbeeck J. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. PHARMACOECONOMICS. ADIS INTERNATIONAL LTD; 2005;23(11):1155–66.
MLA
NEYMARK, N, P LIANES, EF SMIT, et al. “Economic Evaluation of Three Two-drug Chemotherapy Regimens in Advanced Non-small-cell Lung Cancer.” PHARMACOECONOMICS 23.11 (2005): 1155–1166. Print.